Now here’s a businessman with some interesting business strategies. Jon Schultz is the proud owner of some interesting domain names, including,, and

In an interview with The Washington Post, Schultz talks about what may prove to be his most lucrative domain acquisition, Although Schultz’s critics question the morals behind buying up domain names for disasters and disease, granting him the title “merchant of disease domains,” he maintains that his business practices are not seedy, but beneficial for disease research.

“This is not only a mean-spirited article in which Mr. McCoy seeks to impress people with how moral he is by criticizing me for doing nothing but buying a piece of property and looking to sell it at a profit (and sacrificing about $5,000 in domain parking revenue to have a site up with a link where people can make a donation to Doctors Without Borders), but his quotes of me are inaccurate as well,” Schultz said in a response to the Washington Post article. “I am sure he cannot produce a recording of our conversation because the quotes which he provided are not exact quotes and do not accurately portray my sentiments.”

Schultz purchased back in 2008, well before the 2014 Ebola Outbreak in West Africa, which has claimed close to 4,500 lives. After a careful review of page views per day and inquiries he has received over the sale of, which for obvious reasons has become a popular topic in the United States, Schultz has placed his asking price at $150,000. He hopes that he can sell the domain sooner rather than later just in case something is done to “ameliorate” the current outbreak. He has even provided some of his insight into a compound that he says has potential to make a difference in treating diseases like Ebola.

“And not only are we providing a prominent link to Doctors Without Borders on the page that we have up, but we are also providing a nonprofit link to a very scholarly eBook on the possible use of the inexpensive compound BHT as an agent for helping to prevent or cure viral diseases," Schultz added. "That is certainly an idea which merits some consideration by the medical community and governments. However, I have not seen anyone in the medical community or government comment on it to date. I doubt that pharmaceutical companies would conduct clinical trials with BHT as that would cost a lot of money and the substance cannot be patented.”